Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates

Table 6 Utility gain 6 and 12 months post-therapy initiation in anti-TNF responders and non-responders

	Canada	France	UK	Germany	HK
Unadjusted (Mean ± SD)
All users
Index	0.53 ± 0.08	0.53 ± 0.08	0.53 ± 0.07	0.54 ± 0.08	0.53 ± 0.07
6 M after index visit	0.64 ± 0.13	0.63 ± 0.13	0.63 ± 0.13	0.65 ± 0.13	0.62 ± 0.13
12 M after index visit	0.62 ± 0.12	0.61 ± 0.12	0.61 ± 0.11	0.63 ± 0.12	0.60 ± 0.11
Responders
Index	0.55 ± 0.09	0.55 ± 0.09	0.53 ± 0.08	0.55 ± 0.09	0.55 ± 0.08
6 M after index visit	0.68 ± 0.12	0.67 ± 0.12	0.65 ± 0.12	0.69 ± 0.12	0.67 ± 0.11
12 M after index visit	0.65 ± 0.12	0.64 ± 0.12	0.62 ± 0.10	0.66 ± 0.11	0.60 ± 0.10
Non-responders
Index	0.52 ± 0.06	0.52 ± 0.06	0.52 ± 0.07	0.52 ± 0.06	0.52 ± 0.07
6 M after index visit	0.60 ± 0.13	0.59 ± 0.12	0.62 ± 0.14	0.61 ± 0.13	0.59 ± 0.13
12 M after index visit	0.59 ± 0.12	0.58 ± 0.12	0.61 ± 0.12	0.60 ± 0.13	0.59 ± 0.11

ISSN: 1478-7547